Can the NF-κB Pathway be Targeted for Cancer Therapy?
Yes, targeting the NF-κB pathway is a promising strategy in cancer therapy. Several inhibitors that block different components of the pathway are being explored. For instance, proteasome inhibitors like bortezomib can prevent the degradation of IκB, thereby inhibiting NF-κB activation. Additionally, small molecule inhibitors and natural compounds are being investigated for their potential to modulate NF-κB activity.
